GlaxoSmithKline (GSK) to Release Quarterly Earnings on Wednesday

Share on StockTwits

GlaxoSmithKline (NYSE:GSK) is set to post its quarterly earnings results on Wednesday, July 24th. Analysts expect GlaxoSmithKline to post earnings of $0.65 per share for the quarter. GlaxoSmithKline has set its FY 2019 guidance at $1.38-1.44 EPS.

GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.13. The business had revenue of $9.98 billion during the quarter, compared to analysts’ expectations of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 157.04%. On average, analysts expect GlaxoSmithKline to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of NYSE GSK opened at $41.13 on Tuesday. The firm has a 50-day simple moving average of $40.39. The firm has a market capitalization of $101.61 billion, a PE ratio of 13.02, a price-to-earnings-growth ratio of 2.15 and a beta of 0.74. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. GlaxoSmithKline has a 52 week low of $36.41 and a 52 week high of $42.20.

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Stockholders of record on Friday, May 17th were given a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.82%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio (DPR) is 58.86%.

In other news, Director Plc Glaxosmithkline acquired 385,714 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,399,996.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by company insiders.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Cowen reiterated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Morgan Stanley assumed coverage on shares of in a research report on Monday, June 17th. They issued an “equal weight” rating and a GBX 215 ($2.81) target price for the company. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and an average target price of $42.28.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What are the reasons investors use put options?

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Xinyuan Real Estate  to Release Earnings on Friday
Xinyuan Real Estate to Release Earnings on Friday
Qudian  Set to Announce Earnings on Friday
Qudian Set to Announce Earnings on Friday
WM Morrison Supermarkets  Hits New 1-Year Low Following Analyst Downgrade
WM Morrison Supermarkets Hits New 1-Year Low Following Analyst Downgrade
Card Factory  Hits New 12-Month Low Following Analyst Downgrade
Card Factory Hits New 12-Month Low Following Analyst Downgrade
Evelyn Bourke Buys 6,400 Shares of Bank of Ireland Group plc  Stock
Evelyn Bourke Buys 6,400 Shares of Bank of Ireland Group plc Stock
Scott Cochrane Acquires 11,173 Shares of Baillie Gifford UK Growth Fund PLC  Stock
Scott Cochrane Acquires 11,173 Shares of Baillie Gifford UK Growth Fund PLC Stock


© 2006-2019 Ticker Report